Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Joe, Soo Geun ^a   Yoon, Young Hee ^a   Choi, Jeong A ^a   Koh, Jae Young ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; OXYGEN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANIMAL; COMPLICATION; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; RETINA; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCEIN ANGIOGRAPHY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; METFORMIN; MICE; RETINA; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84925740286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119708     Document Type: Article

References (38)

1. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol. 1995; 11: 73-91. PMID: 8689573
2. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013; 120: 106-114. doi: 10.1016/j.ophtha.2012.07.038 PMID: 23031671
3. Stitt AW, Lois N, Medina RJ, Adamson P, Curtis TM. Advances in our understanding of diabetic retinopathy. Clin Sci (Lond). 2013; 125: 1-17.
4. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012; 366: 1227-1239. doi: 10.1056/NEJMra1005073 PMID: 22455417
5. Giuliari GP. Diabetic retinopathy: current and new treatment options. Curr Diabetes Rev. 2012; 8: 32-41. PMID: 22352446
6. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011; 364: 603-615. doi: 10.1056/NEJMoa1007374 PMID: 21323540
7. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol. 2009; 148: 536-543 e532. doi: 10.1016/j.ajo.2009.05.031 PMID: 19660736
8. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994; 35: 101-111. PMID: 7507904
9. Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009; 4: 1565-1573. doi: 10.1038/nprot.2009.187 PMID: 19816419
10. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012; 122: 253-270. doi: 10.1042/CS20110386 PMID: 22117616
11. Group UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-865. PMID: 9742977
12. Dallaglio K, Bruno A, Cantelmo AR, Esposito AI, Ruggiero L, Orecchioni S, et al. Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis. 2014; 35: 1055-1066. doi: 10.1093/carcin/bgu001 PMID: 24419232
13. Liao H, Zhou Q, Gu Y, Duan T, Feng Y. Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep. 2012; 27: 1873-1878. doi: 10.3892/or.2012.1745 PMID: 22469973
14. Xavier DO, Amaral LS, Gomes MA, Rocha MA, Campos PR, Cota BD, et al. Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother. 2010; 64: 220-225. doi: 10.1016/j.biopha.2009.08.004 PMID: 20053525
15. Tan BK, Adya R, Chen J, Farhatullah S, Heutling D, Mitchell D, et al. Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res. 2009; 83: 566-574. doi: 10.1093/cvr/cvp131 PMID: 19414528
16. Esfahanian N, Shakiba Y, Nikbin B, Soraya H, Maleki-Dizaji N, Ghazi-Khansari M, et al. Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells. Mol Med Rep. 2012; 5: 1068-1074. doi: 10.3892/mmr.2012.753 PMID: 22246099
17. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 2009; 113: 101-111. doi: 10.1007/s10549-008-9916-5 PMID: 18256928
18. Hadad SM, Appleyard V, Thompson AM. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 2009; 114: 391. doi: 10.1007/s10549-008-0016-3 PMID: 18421577
19. Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012; 2: 344-355. doi: 10.1158/2159-8290.CD-11-0280 PMID: 22576211
20. Higgins RD, Yu K, Sanders RJ, Nandgaonkar BN, Rotschild T, Rifkin DB. Diltiazem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy. Curr Eye Res. 1999; 18: 20-27. PMID: 10075199
21. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007; 19: 2003-2012. PMID: 17658244
22. Munie M, ryu C, Noorulla S, Rana S, Malach D, Qiao X, et al. Effect of Metformin on the Development and Severity of Diabetic Retinopathy. 2014 The Association for Research in Vision and Ophthalmology. 2014 May 4-8; Orlando, Fla., USA: Thomson Reuters; 2014.(55) p.1069.
23. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011; 13: 483-491. PMID: 21532889
24. Wu B, Li S, Sheng L, Zhu J, Gu L, Shen H, et al. Metformin inhibits the development and metastasis of ovarian cancer. Oncol Rep. 2012; 28: 903-908. doi: 10.3892/or.2012.1890 PMID: 22752027
25. Rivera JC, Sapieha P, Joyal JS, Duhamel F, Shao Z, Sitaras N, et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology. 2011; 100: 343-353. doi: 10.1159/000330174 PMID: 21968165
26. Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of Diabetic Retinopathy. ISRN Ophthalmol. 2013; 2013: 343560. doi: 10.1155/2013/343560 PMID: 24563789
27. Lee J, Kim KE, Choi DK, Jang JY, Jung JJ, Kiyonari H, et al. Angiopoietin-1 guides directional angiogenesis through integrin alphavbeta5 signaling for recovery of ischemic retinopathy. Sci Transl Med. 2013; 5: 203ra127. doi: 10.1126/scitranslmed.3006666 PMID: 24048525
28. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem. 1999; 274: 25130-25135. PMID: 10455194
29. Shibuya M. VEGF-VEGFR Signals in Health and Disease. Biomol Ther (Seoul). 2014; 22: 1-9.
30. Molavi B, Rassouli N, Bagwe S, Rasouli N. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag. 2007; 3: 967-973. PMID: 18200815
31. Lettieri Barbato D, Vegliante R, Desideri E, Ciriolo MR. Managing lipid metabolism in proliferating cells: New perspective for metformin usage in cancer therapy. Biochim Biophys Acta. 2014; 1845: 317-324. doi: 10.1016/j.bbcan.2014.02.003 PMID: 24569230
32. Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A, et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013; 34: 2823-2832. doi: 10.1093/carcin/bgt307 PMID: 24130167
33. Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res. 2014; 159: 355-376. doi: 10.1007/978-3-642-38007-5-21 PMID: 24114491
34. Qu C, Zhang W, Zheng G, Zhang Z, Yin J, He Z. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol Cell Biochem. 2014; 386: 63-71. doi: 10.1007/s11010-013-1845-x PMID: 24096736
35. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009; 137: 482-488. doi: 10.1053/j.gastro.2009.04.013 PMID: 19375425
36. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305. PMID: 15849206
37. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-1625. doi: 10.2337/dc08-2175 PMID: 19564453
38. Ersoy C, Kiyici S, Budak F, Oral B, Guclu M, Duran C, et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract. 2008; 81: 56-60. doi: 10.1016/j.diabres.2008.02.006 PMID: 18358555